1 / 71

GASTRIC TUMOURS

GASTRIC TUMOURS.  Anatomy of the stomach  Aetiology of Gastric cancer  Types of Gastric cancer  Pathology of Gastric Cancer  Evaluation of Gastric Cancer  Treatment of Gastric Cancer. ANATOMY :.

dalton-gaines
Télécharger la présentation

GASTRIC TUMOURS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GASTRICTUMOURS Anatomy of the stomach Aetiology of Gastric cancer Types of Gastric cancer Pathology of Gastric Cancer Evaluation of Gastric Cancer Treatment of Gastric Cancer

  2. ANATOMY: The stomach J-shaped. The stomach has two surfaces (the anterior & posterior), two curvatures (the greater & lesser), two orifices (the cardia & pylorus). It has fundus, body and pyloric antrum.

  3. BLOODSUPPLY: a.The left gastric artery b.Right gastric artery c.Right gastro-epiploic artery d.Left gastro-epiploic artery e.Short gastric arteries The corresponding veins drain into portal system. The lymphatic drainage of the stomach corresponding its blood supply.

  4. Anatomy • Stomach has five layers: • Mucosa • Epithelium, lamina propria, and muscularis mucosae* • Submucosa • Smooth muscle layer • Subserosa • Serosa

  5. AETIOLOGY:  Gastric cancer is the second most common fatal cancer in the world with high frequency in Japan. The disease presents most commonly in the 5th and 6th decades of life and affect males twice as often as females. Contn…

  6. The cause of the disease multistep process but several predisposing factors attributed to cause the disease : a.Environmente.Atrophic gastritis b.Dietf.Chronic gastric ulcer c.Heredity g.Adenomatous polyps d.Achlorhydriah.Blood group A i.H. Pyloric colonisation

  7. TYPESOFGASTRICCANCER: A.Benign Tumours B.Malignant Tumours

  8. TYPESOFGASTRICCANCER: A.Benign Tumours B.Malignant Tumours

  9. THEBENIGNTUMORS: Although benign tumors can occur in the stomach most gastric tumours are malignant.

  10. The benign groups includes:- 1.Non-neoplastic gastric polyps 2.Adenomas 3.Neoplastic gastric polyps 4.Smooth muscles tumours benign (Leiomyomas) 5.Polyposis Syndrome (eg:- Polyposis coli, Juvenile polyps and P.J. Syndrome) 6.Other benign tumours are fibromas, neurofibromas, aberrat pancreas and angiomas.

  11. PATHOLOGYOFGASTRIC(MALIGNANT)TUMOURS:  The gastric cancer may arise in the antrum (50%), the gastric body (30%), the fundus or oesophago-gastric juntion (20%).

  12. TypesofMalignantTumours: a.Adenocarcinoma b.Leiomyosarcoma c.Lymphomas d.Carcinoid Tumours

  13. The macroscopic forms of gastric cancers are classified by (Bormann classification) into:- 1.Polypoid or Proliferative 2.Ulcerating 3.Ulcerating/Infiltrating 4.Diffuse Infiltrating (Linnitus- Plastica)

  14. Microscopically the tumours commonly adenocarcinoma with range of differentiation. The most useful to clinician and epidemiologist is Lauren Histological Classification: a.Intestinal gastric cancer b.Diffuse gastric cancer

  15. Diffuse M:F 1:1 Onset Middle Age 5 yr surv overall <10% Aetiology Diet H. pylori Intestinal M:F 2:1 Onset Middle Age 5 yr surv overall 20% Aetiology Unknown Blood group A association H. pylori Gastric Carcinoma

  16.  Early Gastric Cancer:Defined as cancer whichis confined to the mucosa and submucosa regard- less of lymph nodes status.  Advanced Gastric Cancer: Defined as tumor that has involved the muscularis propria of the stomach wall.

  17. Pathology: Gastric dysplasia ---> precursor of gastric CA Early gastric cancer: Limited to the mucosa and submucosa, regardless of LN status 70% are well differentiated Cure rate is 90% Gastric Neoplasm:

  18. STAGINGOFGASTRICCANCER: a.TNM System b.CT Staging c.PHNS Staging System (Japanese) P-factor (Peritoneal dissemination)  H-factor (The presence of hepatic metastases) N-factor (Lymphnodes involvement) S-factor (Serosal invasion)

  19. TNM Classification System • Distant metastasis (M) MX Presence of distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis (may be further specified according to size of occurrence)

  20. SPREADOFGASTRICCANCER:  The diffuse type spreads rapidly through the submucosal and serosal lymphatic and penetrates the gastric wall at early stage, the intestinal variety remains localized for a while and has less tendency to disseminate. The spread by: 1.Direct (loco regional) 2.Lymphatic 3.Blood (Haematogenous) 4.Transcoelomic

  21. Clinical Manifestation: • Weight loss due to anorexia and early satiety is the most common symptoms • Abdominal pain (not severe) common • Nausea / vomiting • Chronic occult blood loss is common; GIT bleeding (5%) • Dysphagia (cardia involvement)

  22. Clinical Manifestation: • Paraneoplastic syndromes ( Trousseau’s syndrome – thrombophlebitis; acanthosis nigricans – hyperpigmentation of axilla and groin; peripheral neuropathy) • Signs of distant metastasis: • Hepatomegally / ascites • Krukenbergs tumor • Blummers shelf (drop metastasis) • Virchow’s node • Sister Joseph node (pathognomonic of advances dse)

  23. SUMMARY:  Often asymptomatic until late stage.  Marked weight loss  Anorexia  Feeling of abdominal fullness or discomfort  Epigastric mass Iron Deficiency Anaemia Left supraclavicular mass (Troisier’s Sign) Obstructive Jaundice (Secondary in porta hepatitis)  Pelvic mass (Krukenberg)

  24. EVALUATIONOFGASTRICCANCER: History Clinical Examination Investigations The clinical features of gastric cancer may arise from local disease, its complications or its metastases.

  25. INVESTIGATIONS: A.Upper gastero intestinal endoscopy with multiple biopsy and brush cytology B.Radiology: CT Scan of the chest and abdomen USS upper abdomen Barium meal C.Diagnostic laparoscopy

  26. Diagnosis: • UGIS (double contrast) • Endoscopy (Biopsy / Ultrasound) • GOLD STANDARD • Best pre-operative staging • Needle aspiration of LN w/ ultrasound guidance • Can even give preop neoadjuvant tx • CT scan (intravenous and oral contrast): • For pre-operative staging • Whole body Positron Emission Tomography scanning (PET): • Tumor cell preferentially accumulate positron-emitting 18F fluorodeoxyglucose.

  27. Laboratory • Assists in determining optimal therapy. • CBC identifies anemia, with may be caused by bleeding, liver dysfunction, or poor nutrition. • 30% have anemia. • Electrolyte panels and LFTs are also essential to better characterize patients clinical state.

  28. Investigations for patients with gastric cancer • Endoscopy & biopsy • Performance status • Physiological assessment • Cardio-pulmonary function • CT chest & abdomen • EUS (endoscopic ultrasound) • Laparoscopy

  29. CT scanning • Technique • Spiral CT of chest and abdomen

  30. Laparoscopy • Inspect peritoneal surfaces, liver surface. • Identification of advanced disease avoids non-therapeutic laparotomy in 25%. • Patients with small volume metastases in peritoneum or liver have a life expectancy of 3-9 months, thus rarely benefit from palliative resection.

  31. Screening of Gastric Cancer • Patients at risk for gastric CA should undergo yearly endoscopy and biopsy: • Familial adenomatous polyposis • Hereditary nonpolyposis colorectal cancer • Gastric adenomas • Menetrier’s disease • Intestinal metaplasia or dysplasia • Remote gastrectomy or gastrojejunostomy

  32. TREATMENTSOFGASTRICCANCER: Surgery(Early or Advanced Cancer)  Distal tumours which involve the lower ½ (sub-total or partial gasterectomy). Proximal tumours which involve the fundus, cardia or body (total gasterectomy).

  33. Surgical Treatment

  34. TREATMENT: SURGERY: • The only curative tx for gastric cancer • Except: • Can’t tolerate abdominal surgery • Overwhelming metastasis • Palliation is poor w/ non-resective operations • GOAL: resect all tumors, w/ negative margins (5cm) and adequate lymphadenectomy (need for RFS) • Enbloc resection of adjacent organ is done if needed.

  35. TREATMENT: SURGERY: Radical subtotal gastrectomy Standard operation for gastric cancer Organs resected: Distal 75% of stomach 2 cm of duodenum Greater & lesser omentum Ligation of R & L gastric artery and gastroepiploic vesels Billroth II gastojejunostomy

  36. TREATMENT: SURGERY: Radical subtotal gastrectomy Standard operation for gastric cancer If gastric remnant left is small (<20%) do Roux-en-Y reconstruction

  37. Endoscopic Resection of Gastric Carcinoma Criteria: • Tumor < 2cm in size • Node negative • Tumor confined on the mucosa Nodes metastasis is < 1%: • No mucosal ulceration • No lymphatic invasions • <3cm tumor

  38. Treatment of gastric cancer • Endoscopic treatment • EMR (endoscopic mucosal resection) • ablation • Surgery • Multimodal treatment • Neo-adjuvant • Adjuvant • Palliative treatment

  39. Endsocopic mucosal resection • T1 mucosal disease • Minimal risk of LN metastases • Various techniques • Specimen obtained

  40. Distal Pancreatectomy • Associated with marked increase in morbidity & mortality with or without splenectomy • Indications for pancreatectomy: • Direct invasion of the tail of the pancreas • Likelihood of splenic artery nodal involvement

  41. Surgical Treatment

  42.  Inoperable tumours: Whenever possible it is advisable to do even a limited gastric resection. If resection is impossible an anterior gastrojejunostomy.

  43. Indications for Splenectomy • If macroscopic disease can be resected & the operation is potentially curative then en bloc splenectomy or pancreaticosplenectomy is worthwhile. • If it is more palliative then this benefit must be weighed against the potential complications of splenectomy and more extensive operation

More Related